High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients

被引：15
|
作者：
Tréluyer, JM [1 ]
Morini, JP [1 ]
Dimet, J [1 ]
Gorin, I [1 ]
Rey, E [1 ]
Deleuze, J [1 ]
Ceccaldi, PF [1 ]
Escande, JP [1 ]
Pons, G [1 ]
Dupin, N [1 ]
机构：
[1] Univ Paris 05, Grp Hosp Cochin St Vincnet De Paul, AP HP, F-75674 Paris 14, France
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 12期
关键词：
D O I：
10.1128/AAC.46.12.4009-4012.2002
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
To assess the relationship between antiretroviral drug exposure and lipodystrophy, 69 human immunodeficiency virus type 1-infected patients receiving nelfinavir were investigated cross-sectionally. Lipodystrophy was defined by patients' self-report. Nelfinavir trough concentrations in plasma were significantly related to overall lipodystrophy and peripheral fat wasting scores and appeared to be an independent risk factor for lipodystrophy.
引用
收藏
页码：4009 / 4012
页数：4
相关论文
共 50 条
  • [41] Characteristics of metabolic abnormalities and lipodystrophy associated with drug therapy in human immunodeficiency virus-infected children
    Benavides, S
    Koranyi, KI
    Brady, MT
    Nahata, MC
    [J]. PEDIATRIC RESEARCH, 2003, 53 (04) : 332A - 333A
  • [42] Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients
    Maenza, JR
    Keruly, JC
    Moore, RD
    Chaisson, RE
    Merz, WG
    Gallant, JE
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01): : 219 - 225
  • [43] Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review
    Chow D.
    Shikuma C.
    Ritchings C.
    Guo M.
    Rosenblatt L.
    [J]. Infectious Diseases and Therapy, 2016, 5 (4) : 473 - 489
  • [44] Tuberculin sensitivity testing in human immunodeficiency virus-infected patients
    Joob, Beuy
    Wiwanitkit, Viroj
    [J]. HONG KONG MEDICAL JOURNAL, 2013, 19 (06) : 561 - 561
  • [45] Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy
    Singh, N
    Berman, SM
    Swindells, S
    Justis, JC
    Mohr, JA
    Squier, C
    Wagener, MM
    [J]. CLINICAL INFECTIOUS DISEASES, 1999, 29 (04) : 824 - 830
  • [46] SYPHILITIC UVEITIS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED AND NONINFECTED PATIENTS
    BECERRA, LI
    KSIAZEK, SM
    SAVINO, PJ
    MARCUS, DK
    BUCKLEY, RM
    SERGOTT, RC
    BOSLEY, TM
    [J]. OPHTHALMOLOGY, 1989, 96 (12) : 1727 - 1730
  • [47] CLINICAL PHARMACOKINETICS OF CIDOFOVIR IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS
    CUNDY, KC
    PETTY, BG
    FLAHERTY, J
    FISHER, PE
    POLIS, MA
    WACHSMAN, M
    LIETMAN, PS
    LALEZARI, JP
    HITCHCOCK, MJM
    JAFFE, HS
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) : 1247 - 1252
  • [48] Otologic and audiologic evaluation of human immunodeficiency virus-infected patients
    Chandrasekhar, SS
    Connelly, PE
    Brahmbhatt, SS
    Shah, CS
    Kloser, PC
    Baredes, S
    [J]. AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2000, 21 (01) : 1 - 9
  • [49] A study of prothrombotic factors in human immunodeficiency virus-infected patients
    Lanjiwar, Meena
    Kumari, Pushpa
    Khunger, Jitendra Mohan
    Negi, Narender Singh
    [J]. INDIAN JOURNAL OF MEDICAL SPECIALITIES, 2021, 12 (03) : 142 - 146
  • [50] An Update on Heart Transplantation in Human Immunodeficiency Virus-Infected Patients
    Agueero, F.
    Castel, M. A.
    Cocchi, S.
    Moreno, A.
    Mestres, C. A.
    Cervera, C.
    Perez-Villa, F.
    Tuset, M.
    Cartana, R.
    Manzardo, C.
    Guaraldi, G.
    Gatell, J. M.
    Miro, J. M.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (01) : 21 - 28
12345